Merkel Cell Carcinoma: Prognosis, Survival, and Key Factors in This Rare Skin Cancer

The Merkel cell carcinoma (MCC) is a rare but highly aggressive type of skin cancer, characterized by its rapid progression and high mortality rate. This neuroendocrine skin tumor primarily affects older individuals and is associated with risk factors such as ultraviolet radiation exposure, immunosuppression, and infection with the Merkel cell polyomavirus. Despite its rarity, the incidence of MCC has increased in recent decades, underscoring the importance of understanding its prognosis and available treatment strategies.
MCC typically presents as a rapidly growing erythematous nodule in sun-exposed areas. Diagnosis is confirmed through biopsy and immunohistochemical techniques, with the detection of the CK20 protein being crucial to differentiate it from other similar tumors. The five-year survival rate varies between 48% and 63%, depending on factors such as the tumor stage at diagnosis and the presence of metastasis [1].
The treatment of localized MCC generally involves surgical excision with negative margins, followed by adjuvant radiotherapy to reduce the risk of recurrence. In cases of advanced disease, immunotherapy with checkpoint inhibitors, such as nivolumab and avelumab, has shown promising results, improving the life expectancy of patients [2][3].
The prognosis of MCC is generally unfavorable, especially in patients with metastatic disease. Factors such as male sex, advanced age, and immunosuppression are associated with lower survival rates [4]. However, early detection and appropriate treatment can significantly improve clinical outcomes. Ongoing research into targeted therapies and prognostic biomarkers is essential to optimize the management of this rare skin cancer.
Conclusions
Merkel cell carcinoma represents a significant challenge in dermatologic oncology due to its aggressiveness and uncertain prognosis. The combination of surgery, radiotherapy, and immunotherapy offers a comprehensive approach to improve patient survival. Identifying prognostic factors and developing new therapeutic strategies are crucial to addressing the unmet medical needs in the treatment of MCC.
Referencias
- [1] Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022.
- [2] Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.
- [3] Merkel cell carcinoma.
- [4] Incidence, mortality and survival of Merkel cell carcinoma: a systematic review of population-based studies.
Created 14/1/2025